Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Race Oncology Ltd. ( (AU:RAC) ) has provided an update.
Race Oncology Ltd announced that CEO Dr. Daniel Tillett will present at the Gold Coast Investment Showcase on June 25-26, 2025, and host an investor briefing in Brisbane on June 27, 2025. These events aim to engage shareholders and potential investors, offering insights into the company’s latest developments and strategic direction. The presentations are expected to enhance Race Oncology’s visibility and strengthen its position in the biopharmaceutical industry by showcasing its innovative cancer treatment solutions.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is a clinical stage biopharmaceutical company focused on cancer care. Their lead product, bisantrene, is an anticancer drug with a unique clinical history, known for its therapeutic benefits and reduced cardiotoxicity compared to similar drugs. The company is advancing bisantrene for multiple oncology indications and exploring its potential in treating acute myeloid leukemia, while also investigating its effects on the m6A RNA pathway.
Average Trading Volume: 134,324
Technical Sentiment Signal: Sell
Current Market Cap: A$222.4M
See more data about RAC stock on TipRanks’ Stock Analysis page.